The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …

Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …

Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …

Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report
molecular profiling of 230 resected lung adenocarcinomas using messenger RNA …

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of
cancer burden, but existing ctDNA detection methods have insufficient sensitivity or patient …

Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide
substitutions and epigenetic modifications that drive malignant transformation. The Cancer …

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth
factor receptor family having tyrosine kinase activity. Dimerization of the receptor results in …

All cancers arise as a result of changes that have occurred in the DNA sequence of the
genomes of cancer cells. Over the past quarter of a century much has been learnt about …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Lung adenocarcinoma, the most common subtype of non-small cell lung cancer, is
responsible for more than 500,000 deaths per year worldwide. Here, we report exome and …